Apollomics is a clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer.
Company profile
Ticker
APLM, APLMW
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
811218187
Latest filings (excl ownership)
6-K
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
25 Apr 24
EFFECT
Notice of effectiveness
25 Apr 24
EFFECT
Notice of effectiveness
25 Apr 24
424B3
Prospectus supplement
24 Apr 24
424B3
Prospectus supplement
24 Apr 24
F-3/A
Shelf registration (foreign) (amended)
19 Apr 24
F-3/A
Shelf registration (foreign) (amended)
19 Apr 24
F-3
Shelf registration (foreign)
1 Apr 24
F-3
Shelf registration (foreign)
1 Apr 24
20-F
2023 FY
Annual report (foreign)
28 Mar 24
Latest ownership filings
SC 13G
Alpha Intelligence Enterprises Ltd.
27 Feb 24
SC 13D/A
ORBIMED ADVISORS LLC
29 Nov 23
144
Notice of proposed sale of securities
27 Nov 23
SC 13D/A
ORBIMED ADVISORS LLC
20 Nov 23
144
Notice of proposed sale of securities
16 Nov 23
SC 13D/A
ORBIMED ADVISORS LLC
1 Nov 23
144
Notice of proposed sale of securities
30 Oct 23
SC 13D
Yu Guo-Liang
10 Oct 23
144
Notice of proposed sale of securities
5 Oct 23
SC 13D/A
ORBIMED ADVISORS LLC
2 Oct 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Mar 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q4 2023
9.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 3 |
Closed positions | 28 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 82.79 mm |
Total shares | 8.69 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 8.62 mm | $9.82 mm |
Exchange Traded Concepts | 35.67 k | $34.42 mm |
Bensler | 25.09 k | $24.21 mm |
Zullo Investment | 14.85 k | $14.33 mm |